Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
|
|
- Emmeline Cooper
- 5 years ago
- Views:
Transcription
1 Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione e che la presentazione non contiene discussione di farmaci in studio o ad uso off-label
2 CURRENT ANTIVIRAL THERAPY FOR HCV GENOTYPE 1 CHRONIC HEPATITIS Pierluigi Toniutto Medical Liver Transplant Section University of Udine
3 WHY TREAT CHRONIC HEPATITIS C? The disease Common, chronic, and frequently progressive Complications are becoming more common [1,2] Liver failure, HCC First indication for liver transplantation in Europe and US The treatment Viral cure, or SVR, is achievable SVR associated with histologic improvement and gradual regression of fibrosis [3] SVR reduces risk for mortality [4], liver failure and HCC, improves survival [5,6] [1] Kanwal F, et al. Gastroenterology. 2011;140: [2] Shaw JJ, et al. Expert Rev Gastroenterol Hepatol. 2011;5: [3] Poynard T, et al. Gastroenterology. 2002;122: [4] Van de Meer et al. JAMA [5] Craxi A, et al. Clin Liver Dis. 2005;9: [6] Shiratori Y, et al. Ann Intern Med. 2005;142:
4 MILESTONES IN THERAPY OF GENOTYPE 1 HCV CHRONIC HEPATITIS 100 Peginterferon Direct-acting antivirals Standard interferon 1991 Ribavirin IFN 6 mos IFN 12 mos IFN/RBV 6 mos IFN/RBV 12 mos PegIFN 12 mos PegIFN/ RBV 12 mos PegIFN/ RBV/ DAA Adapted from US FDA Antiviral Drugs Advisory Committee Meeting; April 27-28, 2011; Silver Spring, MD.
5 TWO PROTEASE INHIBITORS APPROVED FOR GT1 HCV INFECTION COMBINED WITH PR Protease Inhibitor Recommendations Administration Boceprevir 800 mg TID (every 7-9 hrs) [1,2] Naive to previous therapy Previous treatment failure Compensated cirrhosis Response-guided therapy Take with food All patients initiate therapy with 4-wk pegifn/rbv lead-in phase After completion of lead-in phase, boceprevir should be added to continued pegifn/rbv for wks Telaprevir 750 mg TID (every 7-9 hrs) [2,3] Naive to previous therapy Previous treatment failure Compensated cirrhosis Response-guided therapy Take with food (not low fat) All patients initiate therapy with 12-wk period of triple therapy with telaprevir plus pegifn/rbv Followed by wks of pegifn/rbv 1. Boceprevir [US package insert]. July Ghany MG, et al. Hepatology. 2011;54: Telaprevir [US package insert]. October 2012.
6 ADDITION OF BOC OR TVR TO PEGIFN/RBV IMPROVES SVR IN GENOTYPE 1 PATIENTS PegIFN + RBV BOC/TVR + pegifn* + RBV SVR (%) Treatment Naive [1,2] Relapsers [3,4] 7-15 Partial Responders [3,4] 5 Null Responders [4,5] *BOC was administered with pegifn-α2b; TVR was administered with pegifn-α2a in these trials. 1. Poordad F, et al. N Engl J Med. 2011;364: Jacobson IM, et al. N Engl J Med. 2011;364: Bacon BR, et al. N Engl J Med. 2011;364: Zeuzem S, et al. N Engl J Med. 2011;364: Bronowicki JP, et al. EASL Abstract 11.
7 FURTHER ADVANTAGES OF TRIPLE Vs DUAL ANTIVIRAL THERAPY About 50% of naïve and previous relapsers non cirrhotic patients may be treated with a shorter duration schedule on the basis of their on treatment HCV-RNA decline (RGT) TVR: - eevr (HCV-RNA negative at weeks 4-12 in both naives and previous relapsers), TD 24 weeks (12 weeks for naives RVR carrying IL-28B CC genotypes?) BOC: - HCV-RNA neg at weeks 8-24 in naives, TD 28 weeks - HCV-RNA neg at weeks 8-12 in previous relapsers, TD 36 weeks
8 MAIN DRAWBACKS OF TRIPLE Vs DUAL ANTIVIRAL THERAPY Complexity - Different schedules, different durations Difficult to manage - Side effects and drug to drug interactions - Pill burden: 6 pills/day for TVR and 12 pills/day for BOC (adherence) Costs Availability (in Italy) - Only in certified centres (selected according to regional and non-national rules) - Referral of patients from not authorized centres - Overall access to treatment - Patients parked waiting new antivirals
9 HOW TO SELECT PATIENTS FOR TRIPLE ANTIVIRAL THERAPY General assumptions All patients with HCV related chronic hepatitis should be considered potential candidates for treatment HCV genotype 1 patients who failed dual therapy must be considered potential candidates ONLY for triple therapy On the basis of urgency Priority for patients with sever liver disease (F3-F4) Previous non response to dual therapy On the basis of the probability to respond Less severe disease, favourable predictors of response Comparison with dual therapy success in naives Patient motivation National guidelines (AISF)
10 HOW TO SELECT PATIENTS FOR TRIPLE ANTIVIRAL THERAPY General assumptions All patients with HCV related chronic hepatitis should be considered potential candidates for treatment HCV genotype 1 patients who failed dual therapy must be considered potential candidates ONLY for triple therapy On the basis of urgency Priority for patients with severe liver disease (F3-F4) Comorbidities, age Special situations On the basis of the probability to respond Less severe disease, favourable predictors of response Comparison with dual therapy success in naives National guidelines (AISF)
11 EFFICACY AND SAFETY WORSEN IN ADVANCED LIVER DISEASE Severity of adverse events F0 F1 F2 F3 F4 Probability of cure
12 SVR IN PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS BY RESPONSE AT WK 4 IN LEAD- IN ARM Bruno S et al J Hepatol, 2013.
13 REALIZE: SVR RATES WITH TELAPREVIR BY INCREMENTAL RESPONSE AFTER 4 WEEKS OF LEAD-IN Foster et al, J Hepatol 2013;58:488-94
14 LEAD-IN/IFN SENSITIVITY TEST STRATEGY CAN HELP TO DETERMINE WHOM TO TREAT AMONG PATIENTS WITH ADVANCED LIVER DISEASE 4 wks of pegifn/rbv before BOC or TVR Allows assessment of IFN responsiveness Provides useful information regarding likelihood of SVR with addition of DAA Provides insight into tolerability of pegifn/rbv backbone Elucidates hematologic response to pegifn/rbv, especially in these marginal patients; make needed dose adjustments before addition of DAA Helps to make the decision not to treat patients with worse riskbenefit ratio Is IFN sensitivity modifiable? Vitamin D serum levels vitamin D supplementation
15 AISF Recomandation on the management of Triple Therapy (Peg-IFN + Ribavirin + first generation Protease Inhibitors) for genotype 1 chronic Hepatitis C patients Naives: Triple therapy should be scheduled (high priority) for patients with severe fibrosis (METAVIR score F3) to cirrhosis (F4), with compensated liver disease Child-Pugh class A (A1) Previous treatment failure: In Relapser patients, triple therapy should be scheduled (high priority) for severe fibrosis (F3) and cirrhosis (F4) In Partial responders, triple therapy should be scheduled (high priority) for severe fibrosis (F3) and cirrhosis (F4) In Null responders indication to triple therapy has to be considered carefully, considering the low efficacy and the risk of side effects. Published on line April 24, 2013.
16 CUPIC: RISK OF OCCURRENCE OF DEATH OR SEVERE COMPLICATIONS IN CIRRHOTICS TREATED WITH PI Factors Platelet count > /mm 3 Platelet Count < /mm 3 Albumin >3.5 g/dl 3.4% 4.3% Albumin <3.5 g/dl 7.1% 44.1% Portal HTN is key: HVPG>10 mmhg also predictive Hezode C et al J Hepatol 2013; Rutter EASL 2013 Abst 65.
17 EFFICACY AND SAFETY ARE BETTER IN LESS SEVERE LIVER DISEASE Severity of adverse events F0 F1 F2 F3 F4 Probability of cure
18 IDENTIFICATION OF NAIVE HCV 1 PATIENTS WHO MAY BENEFIT FROM DUAL THERAPY WITH PEG-IFN AND RIBAVIRIN 1210 pts: 287 (24%) with RVR and 467 (39%) with SVR 100% 81% 82% 67% SV R 25% 20% of pts were predicted to have > 80% chance of SVR with dual therapy Andriulli et al. J Hepatol 2013.
19 AISF Recomandation on the management of Triple Therapy (Peg-IFN + Ribavirin + first generation Protease Inhibitors) for genotype 1 chronic Hepatitis C patients Naïve: In patients with fibrosis F0-F2 a 4 weeks PEG/RBV treatment permits to personalize treatment schedule and also to assess patient adherence and tolerance of treatment. Those who achieve an RVR should maintain dual therapy; in patients with detectable HCV-RNA at week 4, the indication to add PI should be evaluated case to case, according to stage of disease and considering the possibility to stop treatment and wait new antiviral drugs (B1) In selected patients with severe fibrosis (F3) and cirrhosis (F4), particularly with severe fibrosis (F3), favourable baseline predictors (IL28B CC genotype or low viral load) or with high risk of side effects with PI, the achievement of RVR may justify to continue dual (PEG/RBV) therapy without addition of PI (B2) Published on line April 24, 2013.
20 AISF Recomandation on the management of Triple Therapy (Peg-IFN + Ribavirin + first generation Protease Inhibitors) for genotype 1 chronic Hepatitis C patients Previous dual treatment failure: In patients with fibrosis F0-F1 independently from previous pattern of non response (REL, PR, NR) triple antiviral therapy should be considered only for selected patients taking into account risk/benefit ratio and - Patient motivation - Comorbidities - Age Published on line April 24, 2013
21 HOW TO SELECT PATIENTS WHO DISCONTINUE TRIPLE THERAPY PREMATURELY FOR LACK OF RESPONSE: THE ROLE OF STOPPING RULES Boceprevir [1,2] Time Point Criteria* Action Wk 12 HCV RNA 100 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue all therapy Wk 8 HCV RNA drop <3 log from baseline Discontinue all therapy Telaprevir [2,3] Time Point Criteria* Action Wk 4 or 12 HCV RNA >1000 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue pegifn/rbv 1. Boceprevir [US package insert]. July Ghany MG, et al. Hepatology. 2011;54: Telaprevir [US package insert]. October AISF Clinical Guidelines; 2013.
22 MAJOR SIDE EFFECTS DURING AVT Dual therapy (Peg-IFN + RBV) - asthenia, headache, nausea, fever, musculo-skeletal pain - anemia, neutropenia - decline in mood, irritability, insomnia - rash Triple therapy (Peg-IFN + RBV + DAA) - TVR: pruritus, rash, anemia, gastro-intestinal disorders - BOC: fatigue, anemia, nausea, diarrhoea, dysgeusia, neutropenia Pegintron EU SmPC; Pegasys EU SmPC; Rebetol EU SmPC; Jacobson IM, et al. NEJM 2011; Sherman KE, et al. NEJM 2011; Zeuzem S, et al. NEJM 2011; Telaprevir EU SmPC; Poordad F, et al. NEJM 2011; Bacon BR, et al. NEJM 2011; Boceprevir EU SmPC
23 ANEMIA MANAGEMENT Ribavirin dose reduction mg at a time - Possibly when HCV-RNA negative Epoetin - Can allows to maintain the dose of RBV - Use if Hb <10 g/dl - Recommended dose: IU/week - *Associated with thromboembolism (3%) - Halving dose if Hb increases by 1 g/week or 2 g/month - Discontinue if Hb >12 g/dl Blood transfusion if Hb <8 g/dl Do not suspend RBV and continue treatment with Peg-IFN + DAA (high risk of resistance) Do not reduce DAA dose (high risk of resistance) *Poordad F et al Gastroenterology in press.
24 RASH MANAGEMENT MILD AND MODERATE (grade 1-2 less than 50% of BSA) Continue triple therapy Not reduce TVR Look for systemic symptoms General indication for skin care Anti-histamine for itching Topical steroids Frequent observation to exclude progression SEVERE (grade 3, more than 50% of BSA) Rare Stop TVR Continue Peg-IFN e RBV; discontinue if rash stable or worsens Look for systemic symptoms General indication for skin care Anti-histamine for itching Topical or systemic steroids Cacoub P, et al. J Hepatol 2012
25 RASH MANAGEMENT SEVERE cutaneous adverse reaction (SCAR, grade 4) Associated with systemic symptoms - Extremely rare - Stop immediately all 3 drugs - Patient should be hospitalized (if necessary in ICU) - Exclude a Stevens-Johnson syndrome or DRESS Systemic symptoms fever anorexia lymphoadenopaties facial edema eosinophilia atypical lymphocytes hepatic and renal involvement SJS: Stevens-Johnson Syndrome DRESS: Drug Reaction Eosinophilia Systemic Symptoms TEN: Toxic Epidermic Necrolysis EM: Erythema Multiforme AGEP: Acute Generalized Exanthematous Pustolosis Cacoub P, et al. J Hepatol 2012
26 DYSGEUSIA Telaprevir Not listed as a frequent event Boceprevir - Metallic taste - Contributes to anorexia and weight loss - Naïve: 37 43% (SoC: 13%) - Experienced: 43 45% (SoC: 11%) Taking BOC capsules with chocolate milk seems to help manage dysgeusia in some patients Jacobson IM, et al. NEJM 2011; Poordad F, et al. NEJM 2011; Bacon BR, et al. NEJM 2011; Boceprevir EU SmPC
27 BOTH BOC AND TVR HAVE POTENTIAL FOR MANY DRUG DRUG INTERACTIONS BOC Strong inhibitor of CYP3A4/5 Partly metabolized by CYP3A4/5 Potential inhibitor of and substrate for P-gp TVR Substrate of CYP3A Inhibitor of CYP3A Substrate and inhibitor of P- gp Most drug drug interactions can be overcome by careful survey of the patient s medications and judicious substitutions during HCV therapy (or just during the period of PI-based triple therapy) See:
28 WHO SHOULD BE TREATED NOW? Pts Who Want Tx Want to be cured of disease Personal or social reasons Plans for pregnancy Social support Pts Who Are Eligible for Tx Eligible for pegifn/ RBV Fit for regimen No contraindications Disease stage Pts Who Are Motivated and Understand... Likelihood of response Risks/benefits of treatment Risk of resistance Possibility of shortened therapy What is coming down the line for their genotype
29 WHO SHOULD BE DEFERRED FOR TREATMENT? Patients with mild disease without signs of fibrosis progression (careful monitor of liver function) Patients with advanced liver disease who do not have any other treatment options (decompensated cirrhosis, renal failure and kidney transplant, IFN intolerant) New antivirals are coming but: - For genotype 1, the first therapeutic regimens available will still be based on the use of IFN and RBV (Sofosbuvir, Simeprevir, Faldaprevir) - They will be associated with a probable increment of costs that could be limit their use in all HCV infected patients - Not yet defined the date of their availability in Europe and, more importantly, in Italy - Patients deferred should be carefully informed of the risks, benefits and complexity of deferring treatment
30 SUMMARY BOC or TVR based triple therapy increases SVR rates over pegifn/rbv alone for all genotype 1 patient populations that have been evaluated On-treatment management techniques including application of RGT algorithms and effective management of adverse events maximize treatment outcomes and mitigate treatment failure
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationBOCEPREVIR (BOC): EVIDENCE FROM TRIALS
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationEfficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationPazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt
Monotematica AISF 2013 Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt Pietro Andreone Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum, Università di Bologna Pisa, 17-19
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationLiver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationHCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo
HCV disease: treatment or deferral? Antonio Craxì Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo antonio.craxi@unipa.it Key factors in deciding to treat or wait Patient factors Urgency
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHCV treament with DAA Side effects: Anemia, Skin Manifestations Pr Patrice CACOUB
HCV treament with DAA Side effects: Anemia, Skin Manifestations Pr Patrice CACOUB Service de Médecine Interne, CNRS UMR 7211, INSERM UMR 959 Université Pierre et Marie Curie Centre National de Référence
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationTreatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon
Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies Advances in treatment of HCV Dr John F Dillon Disclosure slide I have received consulting fees and Honoraria from MSD, Abbott,
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationManagement of adverse effects of triple therapy
Management of adverse effects of triple therapy Giovanni Battista Gaeta Cattedra di Malattie Infettive UOC Epatiti Virali Seconda Università di Napoli Disclosures Advisory board: BMS, Gilead, Janssen Speaker:
More informationTransplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.
Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationPersonalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
More informationHepatitis C Treatment in Oregon
The Hepatitis C Advisory Group, 12/21/2014 Hepatitis C Treatment in Oregon Introduction The rising health care burden of HCV infection in Oregon is occurring at this time of growing interest in containing
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationHepatitis C Treatment
Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationHCV: Beyond the current generation of protease inhibitors
HCV: Beyond the current generation of protease inhibitors Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy antonio.craxi@unipa.it Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationShould all genotype 1 patients be started on triple therapy in Asia-Pacific?
Should all genotype 1 patients be started on triple therapy in Asia-Pacific? 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK),
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationHepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid
Hepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid Caveats on hepatitis C therapy decision making We treat persons with a liver. They
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More informationA Practical Guide to Hepatitis C Management
A Practical Guide to Hepatitis C Management David C. Wolf, M.D., FACP, FACG, AGAF Medical Director of Liver Transplantation Westchester Medical Center Professor of Clinical Medicine New York Medical College
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationDiagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationDAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo
DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated
More information